Structure and function of respiratory syncytial virus surface glycoproteins.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current Topics in Microbiology and Immunology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/978-3-642-38919-1_4PMID 24362685PMCID PMC4211642
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

  2013cited by this paper
• The Small Hydrophobic Protein of the Human Respiratory Syncytial Virus Forms Pentameric Ion Channels*

  2012cited by this paper
• The Secreted G Protein of Human Respiratory Syncytial Virus Antagonizes Antibody-Mediated Restriction of Replication Involving Macrophages and Complement

  2012cited by this paper
• Viroporins: structure and biological functions

  2012cited by this paper
• Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

  2012cited by this paper
• The Respiratory Syncytial Virus G Protein Conserved Domain Induces a Persistent and Protective Antibody Response in Rodents

  2012cited by this paper
• Antibodies to the Central Conserved Region of Respiratory Syncytial Virus (RSV) G Protein Block RSV G Protein CX3C-CX3CR1 Binding and Cross-Neutralize RSV A and B Strains

  2012cited by this paper
• Targeting RSV with vaccines and small molecule drugs.

  2012cited by this paper
• Dual Role of Respiratory Syncytial Virus Glycoprotein Fragment as a Mucosal Immunogen and Chemotactic Adjuvant

  2012cited by this paper
• Genetic Variability of Human Respiratory Syncytial Virus A Strains Circulating in Ontario: A Novel Genotype with a 72 Nucleotide G Gene Duplication

  2012cited by this paper
• In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo

  2012cited by this paper
• Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

  2011cited by this paper
• Identification of nucleolin as a cellular receptor for human respiratory syncytial virus

  2011cited by this paper
• Soluble Respiratory Syncytial Virus Fusion Protein in the Fully Cleaved, Pretriggered State Is Triggered by Exposure to Low-Molarity Buffer

  2011cited by this paper
• Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes

  2011cited by this paper
• Respiratory Syncytial Virus Glycoprotein G Interacts with DC-SIGN and L-SIGN To Activate ERK1 and ERK2

  2011cited by this paper
• Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion

  2010cited by this paper
• Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F

  2010cited by this paper
• Neutralization of Human Respiratory Syncytial Virus Infectivity by Antibodies and Low-Molecular-Weight Compounds Targeted against the Fusion Glycoprotein

  2010cited by this paper
• Direct visualization of the small hydrophobic protein of human respiratory syncytial virus reveals the structural basis for membrane permeability

  2010cited by this paper
• Structural basis of respiratory syncytial virus neutralization by motavizumab

  2010cited by this paper
• Prophylactic Treatment with a G Glycoprotein Monoclonal Antibody Reduces Pulmonary Inflammation in Respiratory Syncytial Virus (RSV)-Challenged Naïve and Formalin-Inactivated RSV-Immunized BALB/c Mice

  2010cited by this paper
• Generation of stable monoclonal antibody-producing BCR+ human memory B cells by genetic programming

  2009cited by this paper
• Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein

  2009cited by this paper
• Respiratory Syncytial Virus Grown in Vero Cells Contains a Truncated Attachment Protein That Alters Its Infectivity and Dependence on Glycosaminoglycans

  2009cited by this paper
• Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.

  2009cited by this paper
• The Secreted Form of Respiratory Syncytial Virus G Glycoprotein Helps the Virus Evade Antibody-Mediated Restriction of Replication by Acting as an Antigen Decoy and through Effects on Fc Receptor-Bearing Leukocytes

  2008cited by this paper
• Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).

  2008cited by this paper
• Interaction between respiratory syncytial virus and glycosaminoglycans, including heparan sulfate.

  2007cited by this paper
• Functional analysis of the N-linked glycans within the fusion protein of respiratory syncytial virus.

  2007cited by this paper
• Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

  2007cited by this paper
• Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps

  2007cited by this paper
• Function of the Respiratory Syncytial Virus Small Hydrophobic Protein

  2007cited by this paper
• Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches.

  2007cited by this paper
• Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function

  2006cited by this paper
• Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation

  2006cited by this paper
• Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy

  2006cited by this paper
• Infection of Ciliated Cells by Human Parainfluenza Virus Type 3 in an In Vitro Model of Human Airway Epithelium

  2005cited by this paper
• The Soluble Form of Human Respiratory Syncytial Virus Attachment Protein Differs from the Membrane-Bound Form in Its Oligomeric State but Is Still Capable of Binding to Cell Surface Proteoglycans

  2004cited by this paper
• Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion.

  2004cited by this paper
• Orally Active Fusion Inhibitor of Respiratory Syncytial Virus

  2004cited by this paper
• Recombinant Sendai Virus Expressing the G Glycoprotein of Respiratory Syncytial Virus (RSV) Elicits Immune Protection against RSV

  2004cited by this paper
• Thermostability of the human respiratory syncytial virus fusion protein before and after activation: implications for the membrane-fusion mechanism.

  2004cited by this paper
• The small hydrophobic (SH) protein accumulates within lipid-raft structures of the Golgi complex during respiratory syncytial virus infection.

  2004cited by this paper
• ERK‐1/2 activity is required for efficient RSV infection

  2004cited by this paper
• Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells.

  2003cited by this paper
• Inhibition of Respiratory Syncytial Virus Fusion by the Small Molecule VP-14637 via Specific Interactions with F Protein

  2003cited by this paper
• Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women.

  2003cited by this paper
• Respiratory Syncytial Virus (RSV) Fusion Protein Subunit F2, Not Attachment Protein G, Determines the Specificity of RSV Infection

  2003cited by this paper
• Major changes in the G protein of human respiratory syncytial virus isolates introduced by a duplication of 60 nucleotides.

  2003cited by this paper
• Effect of proteolytic processing at two distinct sites on shape and aggregation of an anchorless fusion protein of human respiratory syncytial virus and fate of the intervening segment.

  2002cited by this paper
• Respiratory Syncytial Virus Infection of Human Airway Epithelial Cells Is Polarized, Specific to Ciliated Cells, and without Obvious Cytopathology

  2002cited by this paper
• CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein

  2001cited by this paper
• N-Glycans of F Protein Differentially Affect Fusion Activity of Human Respiratory Syncytial Virus

  2001cited by this paper
• Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion

  2001cited by this paper
• Proteolytic Activation of Respiratory Syncytial Virus Fusion Protein

  2001cited by this paper
• Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo.

  2001cited by this paper
• Functional Analysis of Recombinant Respiratory Syncytial Virus Deletion Mutants Lacking the Small Hydrophobic and/or Attachment Glycoprotein Gene

  2001cited by this paper
• Stabilization of short collagen-like triple helices by protein engineering.

  2001cited by this paper
• Involvement of Toll-Like Receptor 4 in Innate Immunity to Respiratory Syncytial Virus

  2001cited by this paper
• Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection.

  2001cited by this paper
• Cleavage of the respiratory syncytial virus fusion protein is required for its surface expression: role of furin.

  2000cited by this paper
• Lung Surfactant Protein A Provides a Route of Entry for Respiratory Syncytial Virus into Host Cells

  2000cited by this paper
• Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection.

  2000cited by this paper
• The Fusion Glycoprotein of Human Respiratory Syncytial Virus Facilitates Virus Attachment and Infectivity via an Interaction with Cellular Heparan Sulfate

  2000cited by this paper
• Glycosaminoglycan Sulfation Requirements for Respiratory Syncytial Virus Infection

  2000cited by this paper
• Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies.

  2000cited by this paper
• Structural characterization of the human respiratory syncytial virus fusion protein core.

  2000cited by this paper
• Surfactant protein-A enhances uptake of respiratory syncytial virus by monocytes and U937 macrophages.

  2000cited by this paper
• Recombinant Respiratory Syncytial Virus Bearing a Deletion of either the NS2 or SH Gene Is Attenuated in Chimpanzees

  1999cited by this paper
• Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment.

  1999cited by this paper
• Identification of a Linear Heparin Binding Domain for Human Respiratory Syncytial Virus Attachment Glycoprotein G

  1999cited by this paper
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

  1998cited by this paper
• Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.

  1998cited by this paper
• Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse

  1997cited by this paper
• Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.

  1997cited by this paper
• Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

  1997cited by this paper
• Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant.

  1997cited by this paper
• Heparin-dependent attachment ofrespiratory syncytial virus (RSV) to host cells

  1997cited by this paper
• Determination of the disulfide bond arrangement of human respiratory syncytial virus attachment (G) protein by matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry

  1997cited by this paper
• Host cell effect upon glycosylation and antigenicity of human respiratory syncytial virus G glycoprotein.

  1996cited by this paper
• Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.

  1996cited by this paper
• The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons

  1994cited by this paper
• A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell—Cell Fusion

  1993cited by this paper
• Membrane orientation and oligomerization of the small hydrophobic protein of human respiratory syncytial virus.

  1993cited by this paper
• Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A.

  1992cited by this paper
• A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

  1992cited by this paper
• Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus.

  1991cited by this paper
• Fatty acid acylation of the fusion glycoprotein of human respiratory syncytial virus.

  1989cited by this paper
• The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species

  1989cited by this paper
• Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies

  1988cited by this paper
• Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus.

  1988cited by this paper
• Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus

  1988cited by this paper
• Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus.

  1987cited by this paper
• Appearance of a soluble form of the G protein of respiratory syncytial virus in fluids of infected cells.

  1987cited by this paper
• Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge

  1986cited by this paper
• Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein.

  1985cited by this paper
• Respiratory syncytial virus envelope glycoprotein (G) has a novel structure.

  1985cited by this paper
• Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus.

  1984cited by this paper
• Respiratory syncytial virus polypeptides. III. The envelope-associated proteins.

  1983cited by this paper

• Molecular mechanism of ziresovir targeting the fusion glycoprotein of respiratory syncytial virus

  2026cites this paper
• RSV vaccine development: advances and fusion protein-focused strategies

  2026cites this paper
• Recommendations on Respiratory Syncytial Virus (RSV) Immunization Strategies for Infants and Young Children in Countries with Year-Round RSV Activity

  2026cites this paper
• The soluble G protein of respiratory syncytial virus promotes viral dissemination via TLR2-mediated NLRP3 priming and pyroptosis

  2026cites this paper
• Mucosal immunization with an adenoviral vector expressing a prefusogenic F protein protects the upper and lower respiratory tracts of cotton rats against live respiratory syncytial virus challenge

  2026cites this paper
• A Novel Unadjuvanted Subunit Respiratory Syncytial Virus Prefusion F Vaccine Induces Potent and Differentiated Functional Immune Responses Compared to AS01-Adjuvanted Arexvy in Older Adults.

  2026cites this paper
• Secretory Expression and Purification of Respiratory Syncytial Virus G and F Ectodomain in Human Cells.

  2025cites this paper
• Mucin‐Inspired Filamentous Sulfated Copolymers Effectively Inhibit Human Respiratory Syncytial Virus (hRSV) Infectivity

  2025cites this paper
• Expression and Purification of Recombinant Respiratory Syncytial Virus Proteins.

  2025cites this paper
• Genome-Wide Analyses of Human Respiratory Syncytial Viruses Provide Insights into Evolutionary Dynamics

  2025cites this paper
• Ethnopharmacological survey of Rwandese medicinal plants used for respiratory infections. Effect of Senecio maranguensis extract against respiratory syncytial virus

  2025cites this paper
• Electrical Readout Strategies of GFET Biosensors for Real-World Requirements

  2025cites this paper
• Molecular Mechanisms of Respiratory Syncytial Virus Pathogenesis.

  2025cites this paper
• Computer‐Aided Technology for Bioactive Protein Design and Clinical Application

  2025cites this paper
• Respiratory syncytial virus fuses with plasma membrane to infect primary cultures of bronchial epithelial cells

  2025cites this paper
• Advances in development of antiviral strategies against respiratory syncytial virus

  2025cites this paper
• Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats.

  2025cites this paper
• Structural basis for childhood antibody recognition of the human metapneumovirus fusion protein

  2025cites this paper
• Design of a peptide-based vaccine against human respiratory syncytial virus using a reverse vaccinology approach: evaluation of immunogenicity, antigenicity, allergenicity, and toxicity

  2025cites this paper
• Neutralizing Antibody Response to the AreXvy Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients: Assessment Against Reference and Seasonal Strains

  2025cites this paper
• Structures of respiratory syncytial virus G bound to broadly reactive antibodies provide insights into vaccine design

  2025influential citation
• The usual suspects: Respiratory Syncytial Virus and Rhinovirus drive asthma development and exacerbation.

  2025cites this paper
• Stabilizing the Shield: C-Terminal Tail Mutation of HMPV F Protein for Enhanced Vaccine Design

  2025cites this paper
• Cetacean coronavirus spikes highlight S glycoprotein structural plasticity

  2025cites this paper
• Nanotechnology-driven enhancement and modulation of immune responses in monkeypox and respiratory syncytial virus nanovaccine research.

  2025cites this paper
• Recent Advances in Long-Acting Antiviral Agents: Innovations in Design and Strategies for Extended Duration.

  2025cites this paper
• Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control.

  2025cites this paper
• Recent advances of the respiratory syncytial virus inhibitors.

  2025cites this paper
• Restricting O-Linked Glycosylation of the Mucin-like Domains Enhances Immunogenicity and Protective Efficacy of a Respiratory Syncytial Virus G Glycoprotein Vaccine Antigen

  2025cites this paper
• Quantification of RSV Antibodies in Human Plasma by Enzyme Immunoassays.

  2025cites this paper
• Deciphering the heparin-binding domain of RSV G protein in host-pathogen interactions

  2025cites this paper
• Molecular and Cellular Mechanisms of Respiratory Syncytial Viral Infection: Its Implications for Prophylactic and Therapeutic Pharmaceuticals

  2025cites this paper
• Pre-Cambrian origin of envelope-carrying retrotransposons in metazoans

  2025influential citation
• Respiratory Syncytial Virus Fusion Activity Syncytia Assay.

  2025cites this paper
• ESAT-6 and CFP-10 reactive IgG in patients with tuberculosis inhibits intracellular bacteria

  2025cites this paper
• Structure-Guided Design of Peptide Inhibitors Targeting Class I Viral Fusion Proteins

  2025cites this paper
• Introduction to Respiratory Syncytial Virus.

  2025cites this paper
• Structural Basis for Childhood Antibody Recognition of The Human Metapneumovirus Fusion Protein

  2025cites this paper
• Functional implications of respiratory syncytial virus F sequence variability: a comparative analysis using contemporary RSV isolates

  2025cites this paper
• Layer-by-Layer Microparticle Vaccines Containing a S177Q Point Mutation in the Central Conserved Domain of the RSV G Protein Improves Immunogenicity

  2025cites this paper
• Recovery of Antibody Immunity After a Resurgence of Respiratory Syncytial Virus Infections

  2025cites this paper
• Microevolution and phylogenomic study of Respiratory Syncytial Virus type A

  2025cites this paper
• Genomic Epidemiology of Respiratory Syncytial Virus in a New England Hospital System, 2024

  2025cites this paper
• RSVPreF3 OA respiratory syncytial virus vaccine in older adults: a profile of its use

  2025cites this paper
• Effective treatments for respiratory syncytial virus infection in children remain elusive but prevention tools are now available

  2025cites this paper
• The link between respiratory syncytial virus (RSV) morphogenesis and virus transmission: Towards a paradigm for understanding RSV transmission in the upper airway.

  2025cites this paper
• Analysis of the surface topology of respiratory syncytial virus particles that form on the surface of virus-infected cells

  2025cites this paper
• A single amino acid mutation alters multiple neutralization epitopes in the respiratory syncytial virus fusion glycoprotein

  2025cites this paper
• Virion stripping: A new role for bacterial proteases

  2025cites this paper
• Immunogenicity evaluation of respiratory syncytial virus prefusogenic-F based virus-like-particles consisting of G and M proteins in mice.

  2025cites this paper
• The recent landscape of RSV vaccine research

  2025cites this paper
• Hospitalizations for respiratory syncytial virus (RSV) in Sicily from 2008 to 2021: clinical features and predictors of severity

  2025cites this paper
• Establishing correlation between in vitro potency and in vivo immunogenicity for mRNA vaccines

  2025cites this paper
• Development and Validation of a New Set of Primers for Identification of Circulating Lineages and Palivizumab/Nirsevimab Resistance in HRSV Isolates from Cabo Verde

  2025cites this paper
• Design and preclinical assessment of mRNA-1345 prefusion F glycoprotein-encoding mRNA vaccine for respiratory syncytial virus.

  2025cites this paper
• Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses

  2025cites this paper
• Molecular characterization of human respiratory syncytial virus in Mexico (season 2023–2024) through whole-genome sequencing

  2025cites this paper
• Genomic characterization and phylogenetic analysis of respiratory syncytial virus F gene in Sri Lanka: a comparative study

  2025cites this paper
• Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3

  2025cites this paper
• Efficacy and safety of respiratory syncytial virus vaccines.

  2025cites this paper
• Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses

  2024cites this paper
• Longitudinal humoral analysis in RSV-infected infants identifies pre-existing RSV strain-specific G and evolving cross-reactive F antibodies.

  2024cites this paper
• Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus

  2024cites this paper
• Epidemiological and Genetic Characteristics of Respiratory Viral Coinfections with Different Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

  2024cites this paper
• Generation of novel respiratory syncytial virus vaccine candidate antigens that can induce high levels of prefusion-specific antibodies.

  2024cites this paper
• Interactions Between Bovine Respiratory Syncytial Virus and Cattle: Aspects of Pathogenesis and Immunity

  2024cites this paper
• A foldon-free prefusion F trimer vaccine for respiratory syncytial virus to reduce off-target immune responses

  2024cites this paper
• Protective efficacy of a recombinant adenovirus expressing novel dual F and HN proteins of bovine parainfluenza virus type 3

  2024cites this paper
• Virus neutralization assays for human respiratory syncytial virus using airway organoids

  2024cites this paper
• Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue

  2024cites this paper
• Genomic characterization of human respiratory syncytial virus circulating in Islamabad, Pakistan, during an outbreak in 2022-2023

  2024cites this paper
• Identification of distinct genotypes in circulating RSV A strains based on variants on the virus replication-associated genes

  2024cites this paper
• Deviations in RSV epidemiological patterns and population structures in the United States following the COVID-19 pandemic

  2024cites this paper
• Molecular characterization of human respiratory syncytial virus strains circulating among hospitalized children in Jordan

  2024cites this paper
• Evidence that an interaction between the respiratory syncytial virus F and G proteins at the distal ends of virus filaments mediates efficient multiple cycle infection.

  2024cites this paper
• Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults

  2024cites this paper
• Antigen specificity shapes antibody functions in tuberculosis

  2024cites this paper
• Landscape of respiratory syncytial virus

  2024cites this paper
• Resurgence of respiratory syncytial virus with dominance of RSV-B during the 2022–2023 season

  2024cites this paper
• Biology of human respiratory syncytial virus: Current perspectives in immune response and mechanisms against the virus

  2024cites this paper
• RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy

  2024cites this paper
• How a paramyxovirus fusion/entry complex adapts to escape a neutralizing antibody

  2024cites this paper
• Computational Insights into the Interaction of the Conserved Cysteine-Noose Domain of the Human Respiratory Syncytial Virus G Protein with the Canonical Fractalkine Binding site of Transmembrane Receptor CX3CR1 Isoforms

  2024cites this paper
• Induction of neutralizing antibody responses by AAV5-based vaccine for respiratory syncytial virus in mice

  2024cites this paper
• Regulation and Crosstalk of Cells and Factors in the Pancreatic Cancer Microenvironment.

  2024cites this paper
• Global progress in clinical research on human respiratory syncytial virus vaccines

  2024cites this paper
• Microbiological and epidemiological features of respiratory syncytial virus

  2024cites this paper
• Design of hepadnavirus core protein-based chimeric virus-like particles carrying epitopes from respiratory syncytial virus

  2024cites this paper
• The RSV roadmap in children: Lessons learned, paths forward.

  2024cites this paper
• Epidemiology and genetic diversity of human respiratory syncytial virus in Belgium between 2011 and 2019

  2024cites this paper
• Mutations in the F protein of the live-attenuated respiratory syncytial virus vaccine candidate ΔNS2/Δ1313/I1314L increase the stability of infectivity and content of prefusion F protein

  2024cites this paper
• Respiratory syncytial virus pulmonary infections in adults – disease burden and prevention

  2024cites this paper
• The role of respiratory syncytial virus G protein in immune cell infection and pathogenesis

  2024cites this paper
• From Forgotten Pathogen to Target for New Vaccines: What Clinicians Need to Know about Respiratory Syncytial Virus Infection in Older Adults

  2024influential citation
• Modulating apoptosis as a novel therapeutic strategy against Respiratory Syncytial Virus infection: insights from Rotenone.

  2024cites this paper
• RSV Vaccine with Nanoparticle-Based Poly-Sorbitol Transporter (PST) Adjuvant Improves Respiratory Protection Against RSV Through Inducing Both Systemic and Mucosal Humoral Immunity

  2024cites this paper
• Molecular Evolutionary Analyses of the Fusion Genes in Human Parainfluenza Virus Type 4

  2024cites this paper
• Respiratory syncytial virus glycoprotein G impedes CX3CR1-activation by CX3CL1 and monocyte function

  2024cites this paper
• A tale of two fusion proteins: understanding the metastability of human respiratory syncytial virus and metapneumovirus and implications for rational design of uncleaved prefusion-closed trimers

  2024cites this paper
• Novel influenza viral vectored vaccine against respiratory syncytial virus

  2024cites this paper